Key Facts
- ✓ Withings unveiled the Body Scan 2 at CES 2026 with a price tag of $599.95.
- ✓ The device features eight electrodes on the scale and four within a retractable handle for upper-body data.
- ✓ It focuses on cardiovascular and metabolic health metrics.
- ✓ The Body Scan 2 is scheduled for a Q2 2026 release, pending FDA clearance on some metrics.
Quick Summary
Withings has officially announced the Body Scan 2 at CES 2026, marking a new entry in the high-end smart scale market. Priced at $599.95, the device is designed to function as a comprehensive 'longevity station' with a specific emphasis on cardiovascular and metabolic health metrics.
The device retains the distinctive form factor of the original model, featuring a base unit with eight electrodes and a retractable handle containing four additional electrodes. This design allows the scale to capture upper-body data, a capability that distinguishes it from standard smart scales which typically rely only on foot sensors. By integrating data from the entire body, the Body Scan 2 aims to deliver superior accuracy in body composition analysis.
Withings plans to make the Body Scan 2 available in Q2 2026. However, the launch is currently pending FDA clearance for certain metrics included in the device's feature set.
Design and Technology 🛠️
The Body Scan 2 utilizes a sophisticated electrode system to gather biometric data. The device is equipped with eight electrodes located directly on the scale's platform. Additionally, it includes a retractable handle that houses four more electrodes.
This handle is the key differentiator for the device. Most smart scales on the market rely exclusively on foot electrodes. They use data from the lower body to extrapolate total body composition. By contrast, the Body Scan 2 captures data from the upper body via the handle. This method allows for a more precise measurement of body segments, potentially offering users a more accurate representation of their physical health.
The design philosophy mirrors that of the original Body Scan, maintaining the integration of the handle into the scale's overall footprint. This continuity suggests a commitment to the specific technology stack that allows for this level of detailed analysis.
Health Focus and Accuracy 📊
Withings has positioned the Body Scan 2 with a tighter focus on specific health indicators. The primary areas of measurement are cardiovascular and metabolic health. This represents a refinement of the device's utility, moving beyond simple weight tracking.
The inclusion of the handle significantly impacts the accuracy of the readings. By incorporating upper-body data, the device avoids the estimation errors inherent in lower-body-only systems. The ability to measure specific body segments provides a granular view of body composition that is rare in consumer-grade scales.
Key features of the device include:
- Eight electrodes on the scale platform
- Four electrodes in the retractable handle
- Focus on cardiovascular and metabolic metrics
- Enhanced accuracy through full-body data integration
Availability and Regulatory Status 📅
The release schedule for the Body Scan 2 has been set for the second quarter of 2026. This places the launch in the middle of the year, following its unveiling at CES 2026.
However, the timeline is not yet guaranteed. Withings noted that the availability of the device is pending FDA clearance. This clearance is specifically required for certain metrics that the device measures. Regulatory approval is a standard but critical step for health-focused devices in the United States.
Until the FDA provides clearance, the Q2 2026 release date remains a target rather than a confirmed launch window. Consumers interested in the device will need to wait for official regulatory sign-off before the product hits the market.
Market Position and Conclusion 🏆
The Body Scan 2 enters a competitive market for smart health devices. At a price point of $599.95, it sits at the premium end of the spectrum. Withings is leveraging the unique retractable handle technology to justify this positioning, offering functionality that standard smart scales cannot match.
The device represents a broader trend in consumer electronics toward integrated health monitoring. By focusing on cardiovascular and metabolic health, Withings is targeting users who want detailed insights into their wellness without visiting a medical facility. The pending FDA clearance underscores the company's intent to market the device as a serious medical-grade tool.
Ultimately, the Body Scan 2 builds upon the foundation of its predecessor. It refines the focus and awaits regulatory approval. If cleared, it will offer consumers a highly accurate method for tracking comprehensive body composition metrics starting in Q2 2026.
